Literature DB >> 11007674

Increased prevalence of polycystic kidney disease type 2 among elderly polycystic patients.

R Torra1, C Badenas, L Pérez-Oller, J Luis, S Millán, C Nicolau, F Oppenheimer, M Milà, A Darnell.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is genetically heterogeneous, with at least three chromosomal loci (PKD1, PKD2, and PKD3) accounting for the disease. Mutations in the PKD2 gene, on the long arm of chromosome 4, are estimated to be responsible for 15% of the cases of ADPKD, based on linkage studies. PKD2 is a milder form of the disease, with a mean age of end-stage renal disease (ESRD) approximately 20 years later than PKD1. The object of this study is to determine the proportion of elderly patients with ADPKD with ESRD who harbor mutations in the PKD2 gene. We analyzed all exons and intron-exon boundaries of the PKD2 gene by single-strand conformation polymorphism analysis and silver staining technique in 46 patients with ADPKD who reached ESRD after the age of 63 years or were not yet undergoing renal replacement therapy (RRT) by that age. We performed exactly the same studies in a control group of 40 patients with ADPKD with unknown gene status aged younger than 63 years. In 22 patients, a mutation in the PKD2 gene was defined: 18 of 46 patients from the elderly group and 4 of 40 patients from the control group. We identified 14 different mutations: 4 nonsense mutations, 1 missense mutation, 5 small deletions, 2 insertions, 1 deletion of the whole PKD2 gene, and 1 splicing mutation. Five of these mutations previously were described by our group. Three of the mutations reported in the present study are recurrent. The prevalence of PKD2 disease among elderly patients with ADPKD undergoing RRT is 39.1%, almost three times the prevalence of the disease in the general ADPKD population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11007674     DOI: 10.1053/ajkd.2000.17619

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family.

Authors:  Long-Jun Wu; Tara-Beth Sweet; David E Clapham
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Emilie Cornec-Le Gall; Marie-Pierre Audrézet; Annick Rousseau; Maryvonne Hourmant; Eric Renaudineau; Christophe Charasse; Marie-Pascale Morin; Marie-Christine Moal; Jacques Dantal; Bassem Wehbe; Régine Perrichot; Thierry Frouget; Cécile Vigneau; Jérôme Potier; Philippe Jousset; Marie-Paule Guillodo; Pascale Siohan; Nazim Terki; Théophile Sawadogo; Didier Legrand; Victorio Menoyo-Calonge; Seddik Benarbia; Dominique Besnier; Hélène Longuet; Claude Férec; Yannick Le Meur
Journal:  J Am Soc Nephrol       Date:  2015-07-06       Impact factor: 10.121

Review 3.  Molecular diagnostics for autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Determinants of renal disease variability in ADPKD.

Authors:  Peter C Harris; Sandro Rossetti
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

Review 5.  Why kidneys fail in autosomal dominant polycystic kidney disease.

Authors:  Jared J Grantham; Sumanth Mulamalla; Katherine I Swenson-Fields
Journal:  Nat Rev Nephrol       Date:  2011-08-23       Impact factor: 28.314

6.  Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kyongtae T Bae; Wen Zhou; Chengli Shen; Douglas P Landsittel; Zhiyuan Wu; Cheng Tao; Arlene B Chapman; Vicente E Torres; Alan S L Yu; Michal Mrug; William M Bennett; Peter C Harris
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-14       Impact factor: 8.237

7.  Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin.

Authors:  Djalila Mekahli; Jean-Paul Decuypere; Eva Sammels; Kirsten Welkenhuyzen; Joost Schoeber; Marie-Pierre Audrezet; Anniek Corvelyn; Georges Dechênes; Albert C M Ong; Martijn J Wilmer; Lambertus van den Heuvel; Geert Bultynck; Jan B Parys; Ludwig Missiaen; Elena Levtchenko; Humbert De Smedt
Journal:  Pflugers Arch       Date:  2013-11-06       Impact factor: 3.657

Review 8.  The genetics of vascular complications in autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Sandro Rossetti; Peter C Harris
Journal:  Curr Hypertens Rev       Date:  2013-02

9.  High Resolution Melt analysis for mutation screening in PKD1 and PKD2.

Authors:  Stanislas Bataille; Yvon Berland; Michel Fontes; Stéphane Burtey
Journal:  BMC Nephrol       Date:  2011-10-18       Impact factor: 2.388

10.  Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic.

Authors:  Caroline Robinson; Thomas F Hiemstra; Deborah Spencer; Sarah Waller; Laura Daboo; Fiona E Karet Frankl; Richard N Sandford
Journal:  BMC Nephrol       Date:  2012-08-03       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.